Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.
BACKGROUND
Antiangiogenesis is a promising therapy for advanced hepatocellular carcinoma (HCC), but the effects are difficult to be evaluated. Pazopanib (GW786034B) is a pan-vascular endothelial growth factor receptor inhibitor, the antitumor effects or antiangiogenic effects haven't been investigated in HCC.


METHODS
In vitro direct effects of pazopanib on human HCC cell lines and endothelial cells were evaluated. In vivo antitumor effects were evaluated in three xenograft nude mice models. In the subcutaneous HCCLM3 model, intratumoral blood perfusion was detected by contrast-enhanced ultrasonography (CEUS), and serial quantitative parameters were profiled from the time-intensity curves of ultrasonograms.


RESULTS
In vitro proliferation of various HCC cell lines were not inhibited by pazopanib. Pazopanib inhibited migration and invasion and induced apoptosis significantly in two HCC cell lines, HCCLM3 and PLC/PRF/5. Proliferation, migration, and tubule formation of human umbilical vein endothelial cells were inhibited by pazopanib in a dose-dependent manner. In vivo tumor growth was significantly inhibited by pazopanib in HCCLM3, HepG2, and PLC/PRF/5 xenograft models. Various intratumoral perfusion parameters changed over time, and the signal intensity was significantly impaired in the treated tumors before the treatment efficacy on tumor size could be observed. Mean transit time of the contrast media in hotspot areas of the tumors was reversely correlated with intratumoral microvessel density.


CONCLUSIONS
Antitumor effects of pazopanib in HCC xenografts may owe to its antiangiogenic effects, and the in vivo antiangiogenic effects could be evaluated by quantitative CEUS.
Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, People's Republic of China.
Xiao-Dong
XD
Zhu
Ju-Bo
JB
Zhang
Pei-Li
PL
Fan
Yu-Quan
YQ
Xiong
Peng-Yuan
PY
Zhuang
Wei
W
Zhang
Hua-Xiang
HX
Xu
Dong-Mei
DM
Gao
Ling-Qun
LQ
Kong
Lu
L
Wang
Wei-Zhong
WZ
Wu
Zhao-You
ZY
Tang
Hong
H
Ding
Hui-Chuan
HC
Sun
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects / Q000473:pathology; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D056945:Hep G2 Cells; D006801:Humans; D007089:Image Enhancement; D007191:Indazoles; D008114:Liver Neoplasms, Experimental / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D011743:Pyrimidines / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*; D047368:Tumor Burden / Q000187:drug effects; D014463:Ultrasonography / Q000379:methods; D023041:Xenograft Model Antitumor Assays
D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib
Nat Clin Pract Oncol. 2008 Jul;5(7):378-91
18560389
Dig Liver Dis. 2007 Feb;39(2):187-95
17208526
Clin Cancer Res. 2009 Aug 1;15(15):4838-46
19638466
Radiat Res. 1999 May;151(5):580-9
10319731
J Cancer Res Clin Oncol. 2004 Aug;130(8):460-8
15146329
J Hepatol. 2004 Nov;41(5):864-80
15519663
Cancer Res. 2005 May 1;65(9):3691-9
15867364
Radiology. 1998 Nov;209(2):387-93
9807563
Hepatology. 2005 Nov;42(5):1208-36
16250051
Cancer Res. 2008 Sep 1;68(17):7042-9
18757418
Aliment Pharmacol Ther. 2006 Jun 1;23(11):1535-47
16696801
Radiology. 2006 Jul;240(1):73-81
16793972
AJR Am J Roentgenol. 2001 Oct;177(4):783-8
11566673
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
Nat Rev Cancer. 2008 Aug;8(8):579-91
18596824
Radiology. 2006 Jun;239(3):730-9
16714458
Ultrasound Med Biol. 2003 Oct;29(10):1421-30
14597339
Hepatology. 2008 Jan;47(1):97-104
18069697
Eur Radiol. 2001;11(8):1338-44
11519540
Invest Radiol. 2006 Jan;41(1):15-21
16355035
Nat Med. 2001 Sep;7(9):987-9
11533692
Hepatol Res. 2008 Mar;38(3):281-90
17908168
Eur Radiol. 2004 Feb;14(2):309-17
14531000
J Hepatol. 2008 May;48(5):848-57
18328590
J Clin Oncol. 2007 May 1;25(13):1753-9
17470865
Mol Cancer Ther. 2007 Jul;6(7):2012-21
17620431
Oncology. 2007;72 Suppl 1:30-44
18087180
Cancer Res. 2003 Dec 1;63(23):8264-70
14678984
J Clin Oncol. 2008 Jun 20;26(18):2992-8
18565886
Oncologist. 2008 Feb;13(2):120-5
18305056
Gynecol Oncol. 1998 Nov;71(2):270-7
9826471
Nat Rev Cancer. 2002 Oct;2(10):727-39
12360276
AJR Am J Roentgenol. 2006 May;186(5):1423-30
16632740
Gene Ther. 2007 Jan;14(2):108-17
16943854
Cardiovasc Intervent Radiol. 1999 Nov-Dec;22(6):486-92
10556408
J Cereb Blood Flow Metab. 2000 Dec;20(12):1709-16
11129787
J Clin Oncol. 2006 Jul 10;24(20):3293-8
16829653
J Cancer Res Clin Oncol. 2004 Jun;130(6):307-19
15034787
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
J Clin Oncol. 2008 Jun 1;26(16):2707-16
18509183
Cancer. 2008 Jan 15;112(2):250-9
18041064
Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19478-83
17164332